Form 4: 2seventy bio Director Maus Reports Acquisition by Bristol-Myers Squibb, Shares Converted to Cash

Director Marcela V. Maus reports the disposition of shares and stock options in 2seventy bio, Inc. following the merger with Bristol-Myers Squibb, where shares were converted to cash at $5.00 per share.

Summary

• Marcela V. Maus, a director of 2seventy bio, Inc., filed a Form 4 detailing changes in beneficial ownership following the company's acquisition by Bristol-Myers Squibb Company.
• The filing reports transactions occurring on May 13, 2025, related to the merger agreement.
• As part of the merger, 2seventy bio was acquired by Bristol-Myers Squibb through a cash tender offer at a price of $5.00 per share.
• Shares of common stock held by the reporting person were tendered in exchange for the merger consideration.
• Outstanding restricted stock units (RSUs) became fully vested and were converted into the right to receive cash equal to the merger consideration for each underlying share.
• Stock options with an exercise price less than $5.00 were converted into the right to receive cash equal to the difference between the merger consideration and the exercise price.
• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.
• The reporting person disposed of 12,050 shares of common stock and 11,702 shares of common stock, and now owns 0 shares.
• 24,100 stock options were converted to cash.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a cash exit for shareholders, but it also means the company will no longer be publicly traded. The score reflects the certainty of the deal completion and the cash value received by shareholders.

Positives

• Shareholders received $5.00 per share in cash as part of the acquisition.
• RSU holders received cash for their units, which became fully vested upon the merger.
• Option holders with in-the-money options received cash for the difference between the merger price and the exercise price.

Negatives

• Out-of-the-money stock options were cancelled without any compensation.
• The company is no longer publicly traded.

Risks

• There are no specific risks mentioned in this document, as it primarily reports the completion of a merger.

Future Outlook

The document does not contain any forward-looking statements, as it reports the completion of a merger.

Industry Context

The acquisition of 2seventy bio by Bristol-Myers Squibb reflects ongoing consolidation in the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Comparison to Industry Standards

• Merger and acquisition activity in the biotech sector is common, with valuations varying based on the target company's pipeline, technology, and market potential.
• Comparable acquisitions in the biotech space often involve a premium paid over the target's pre-announcement share price, reflecting the acquirer's assessment of the target's future value.
• The $5.00 per share acquisition price needs to be compared to the trading price of TSVT before the announcement to assess the premium paid by Bristol-Myers Squibb.

Stakeholder Impact

• Shareholders received cash for their shares.
• Employees of 2seventy bio are now part of Bristol-Myers Squibb.
• The merger may impact the company's research and development programs.

Key Dates

Keywords

Merger, Acquisition, Bristol-Myers Squibb, 2seventy bio, Form 4, Beneficial Ownership, Cash Tender Offer, Stock Options, RSUs